Navigation Links
Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B
Date:10/17/2011

OXFORD, England, October 18, 2011 /PRNewswire/ --

-- Third ocular product partnered with Sanofi approved to enter clinical development --

Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the Phase I/IIa clinical development of UshStat®, a novel gene-based treatment for Usher syndrome type 1B.  UshStat® was designed and developed by Oxford BioMedica using the Company's proprietary LentiVector® platform technology and is the third programme to enter clinical development under the Phase I/II ocular collaboration agreement signed with Sanofi in April 2009.

The approval of the IND follows the decision by the US Recombinant DNA Advisory Committee (RAC) to approve the UshStat® Phase I/IIa protocol in May 2011.  The open label, dose escalation Phase I/IIa study will enrol up to 18 patients with Usher syndrome type 1B at the Oregon Health and Science University's Casey Eye Institute, Portland, Oregon.  The study, led by Professor Richard Weleber, will evaluate three dose levels for safety, tolerability and aspects of biological activity and is expected to be initiated by the end of 2011.

Usher syndrome is the most common form of deaf-blindness which affects approximately 30,000-50,000 patients in the US and Europe.  One of the most common subtypes is Usher syndrome type 1B.  The disease is caused by a mutation of the gene encoding myosin VIIA (MY07A), which leads to progressive retinitis pigmentosa combined with a congenital hearing defect.  UshStat® uses the Company's LentiVector® platform technology to deliver a corrected version of the MYO7A gene to address the vision loss associated with the disease.  O
'/>"/>

SOURCE Oxford BioMedica plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
2. Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb
3. Oxford Finance Corporation Sponsors 2010 Mid-Atlantic Bio
4. Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio
5. Oxford Finance Corporation Hires Dr. Killu Sanborn to Support Life Science Business Development in Western North America
6. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
7. Oxford BioTherapeutics Appoints Michael Moore as Chairman
8. Oxford Performance Materials Introduces OXPEKK PermettaTM High Performance Polymer Films
9. TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford
10. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
11. Bavarian Nordics Case Against Oxford BioMedica
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... NEW YORK , Sept. 19, 2014  An ... common forms of inherited neuropathies – Charcot-Marie-Tooth disease (CMT) ... feet and legs, causing extreme muscle atrophy, weakness, and ... in the US and millions worldwide. CMT is a ... use of their legs, requiring mobility devices such as ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Barnhardt ... Product Label for its Organic Cotton . The ... amount of renewable biobased ingredients meets or exceeds levels ... materials composed in whole or in significant part of ... will allow our Organic cotton to be immediately identified ...
(Date:9/18/2014)... USA (PRWEB) September 18, 2014 Bipartisan ... of a bill designed to stimulate development and commercialization ... is being praised by leaders of SPIE, the ... the Revitalizing American Manufacturing and Innovation (RAMI) Act, now ... bill’s authors have said they are optimistic that it ...
(Date:9/18/2014)... Sept. 18, 2014  Health Enhancement Products, Inc. (OTCQB: HEPI), ... algae bioactive compounds and metabolic processes, is pleased to announce ... of directors. Ms. Nola E. Masterson , a ... the board effective September 17, 2014. "We,re ... join our board," states Andrew Dahl , President and ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... MONTREAL , Feb. 1 /PRNewswire-FirstCall/ - ICBS Ltd. (OTCPK: ... TOGS(TM) 3000 bio-photonic incubation & detection systems, which the company will ... 100% accuracy in the detection of Total Coli forms and E. ... to introduce the new TOGS(TM) 3000 in the U.S, and overseas." ...
... The ... as a regulatory consultant after retiring from Eli Lilly & Co. Dr. ... human pharmaceutical products, including director of regulatory affairs and clinical research. Dr. ... submissions. , ...
... Data Demonstrating a 35% Overall Response Rate with a ... Relapsed or Relapsed/Refractory Waldenstrom,s Macroglobulinemia to be Published in ... Journal of Clinical Cancer Research , QUÉBEC CITY, ... AEZS ; TSX: AEZ) (the "Company"), a late-stage ...
Cached Biology Technology:BioSpec Global Solutions Inc, takes delivery of new TOG's 3000 Home edition for the U.S. and international markets 2Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 2Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 3Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 4Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 5
(Date:9/18/2014)... stressed they are often grouchy, grumpy, nasty, distracted or ... EPFL have just highlighted a fundamental synaptic mechanism that ... of social skills and cognitive impairment. When triggered by ... the brain. This was revealed by a work published ... team went to look for answers in a region ...
(Date:9/18/2014)... in the protective tentacles of host anemones, but new ... of kilometres across the open ocean. Although the process ... this is the first time that the high level ... , Dr Steve Simpson, Senior Lecturer in Marine Biology ... colleagues from the Australian Research Council Centre of Excellence ...
(Date:9/17/2014)... doctoral student have designed a device based on a ... and dew., The device could provide water in drought-stricken ... Cheng Luo, professor in the Mechanical & Aerospace Engineering ... College of Engineering department, published "Bioinspired Plate-Based Fog Collectors" ... Society) Applied Materials & Interfaces ...
Breaking Biology News(10 mins):How stress tears us apart 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3Shorebird's beak inspires UT Arlington research on water collection 2
... mothers than duller birds, according to a new study led ... see ultra-violet (UV) light. While the crown of a blue ... has the added dimension of appearing UV-reflectant. , The three-year ... University of California Davis, USA and the University of Glasgow, ...
... Dartmouth researchers has uncovered a protein that plays a vital ... key step in improving the production and quality of crops ... journal PNAS . The team included researchers ... Lausanne. Plant roots use their endodermis, or inner skin, ...
... stem cells and DNA-cutting protein from meningitis bacteria, researchers ... have created an efficient way to target and repair ... Aug. 12, 2013) in the Proceedings of the ... the novel technique is much simpler than previous methods ...
Cached Biology News:Bright birds make good mothers 2New gene repair technique promises advances in regenerative medicine 2
Imject Freund's Incomplete Adjuvant (FIA)...
... to slightly cloudy liquid. Yellow, oily, ... set, each containing 10 ml of ... following proportions by weight: 85% Drakeol ... emulsifier), and 0.1% Mycobacterium butyricum ...
... Although there have been many modifications to ... defined media, salt solutions still play an important ... to maintain the pH and osmotic balance in ... water and essential inorganic ions, is as valuable ...
Request Info...
Biology Products: